Refametinib | B1889

Refametinib (BAY 86-9766; previously RDEA119) is a highly selective and potent orally available inhibitor of MEK 1 and MEK 2. It displays potent in vitro and in vivo antitumor activity in multiple preclinical cancer models, including melanoma, colorectal cancer, non-small cell lung cancer, epidermal carcinoma, and HCC.

Refametinib (BAY 86-9766; previously RDEA119) is a highly selective and potent orally available inhibitor of MEK 1 and MEK 2. It displays potent in vitro and in vivo antitumor activity in multiple preclinical cancer models, including melanoma, colorectal cancer, non-small cell lung cancer, epidermal carcinoma, and HCC.

B1889 | Refametinib DataSheet

Alternate Name/Synonyms: N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; BAY 86-9766

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 923032-37-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₉H₂₀F₃IN₂O₅S

Molecular Weight: 572.34

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>5 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A highly selective and potent orally available inhibitor of MEK 1 and MEK 2.

MDL Number: N/A

PubChem CID: 44182295

SMILES: COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F

InChi: InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1

InChi Key: RDSACQWTXKSHJT-NSHDSACASA-N